These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33309390)

  • 1. With crisis comes opportunity: Unanticipated benefits resulting from pivots to take-home naloxone (THN) programs during the COVID-19 pandemic.
    Courser MW; Raffle H
    J Subst Abuse Treat; 2021 Mar; 122():108220. PubMed ID: 33309390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naloxone and the Inner City Youth Experience (NICYE): a community-based participatory research study examining young people's perceptions of the BC take home naloxone program.
    Mitchell K; Durante SE; Pellatt K; Richardson CG; Mathias S; Buxton JA
    Harm Reduct J; 2017 Jun; 14(1):34. PubMed ID: 28592287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of take-home naloxone programs in Australia.
    Dwyer R; Olsen A; Fowlie C; Gough C; van Beek I; Jauncey M; Lintzeris N; Oh G; Dicka J; Fry CL; Hayllar J; Lenton S
    Drug Alcohol Rev; 2018 May; 37(4):440-449. PubMed ID: 29744980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knowledge of naloxone and take-home naloxone programs among a sample of people who inject drugs in Australia: Variations across capital cities.
    Dietze PM; Stare M; Cogger S; Nambiar D; Olsen A; Burns L; Lenton S
    Drug Alcohol Rev; 2018 May; 37(4):457-463. PubMed ID: 29744979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rapid assessment of take-home naloxone provision during COVID-19 in Europe.
    McDonald R; Eide D; Abel-Ollo K; Barnsdale L; Carter B; Clausen T; Day E; Fonseca F; Holmén E; Horsburgh K; Kelleher M; Kåberg M; Ladenhauf M; McAuley A; Metrebian N; Neale J; Parkin S; Ratcliffe K; Rintoul C; Smith J; Stifanoviciute V; Torrens M; Thiesen H; Strang J
    Int J Drug Policy; 2022 Sep; 107():103787. PubMed ID: 35849935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alberta's provincial take-home naloxone program: A multi-sectoral and multi-jurisdictional response to overdose.
    Freeman LK; Bourque S; Etches N; Goodison K; O'Gorman C; Rittenbach K; Sikora CA; Yarema M
    Can J Public Health; 2017 Nov; 108(4):e398-e402. PubMed ID: 29120311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives.
    Lintzeris N; Monds LA; Bravo M; Read P; Harrod ME; Gilliver R; Wood W; Nielsen S; Dietze PM; Lenton S; Shanahan M; Jauncey M; Jefferies M; Hazelwood S; Dunlop AJ; Greenaway M; Haber P; Ezard N; Malcom A
    Drug Alcohol Rev; 2020 Jan; 39(1):55-65. PubMed ID: 31774221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
    Sajwani HS; Williams AV
    Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overdose and take-home naloxone in emergency settings: A pilot study examining feasibility of delivering brief interventions addressing overdose prevention with 'take-home naloxone' in emergency departments.
    Black E; Monds LA; Chan B; Brett J; Hutton JE; Acheson L; Penm J; Harding S; Strumpman D; Demirkol A; Lintzeris N
    Emerg Med Australas; 2022 Aug; 34(4):509-518. PubMed ID: 35021268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rethinking 'carriage' of take-home naloxone.
    McDonald R; Parkin S; Eide D; Neale J; Clausen T; Metrebian N; Carter B; Strang J
    Int J Drug Policy; 2021 Sep; 95():103253. PubMed ID: 33848942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lessons learned from ramping up a Canadian Take Home Naloxone programme during a public health emergency: a mixed-methods study.
    Young S; Williams S; Otterstatter M; Lee J; Buxton J
    BMJ Open; 2019 Oct; 9(10):e030046. PubMed ID: 31662368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design details for overdose education and take-home naloxone kits: Codesign with family medicine, emergency department, addictions medicine and community.
    Sellen K; Goso N; Halleran L; Mulvale-Fletcher A; Sarmiento F; Ligabue F; Handford C; Klaiman M; Milos G; Wright A; Charles M; Sniderman R; Hunt R; Parsons JA; Leece P; Hopkins S; Shahin R; Jüni P; Morrison L; Campbell DM; Strike C; Orkin A;
    Health Expect; 2022 Oct; 25(5):2440-2452. PubMed ID: 35909312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with take-home naloxone kit usage in British Columbia: an analysis of administrative data.
    Lei V; Ferguson M; Geiger R; Williams S; Liu L; Buxton JA
    Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):25. PubMed ID: 35361228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accessing Take-Home Naloxone in British Columbia and the role of community pharmacies: Results from the analysis of administrative data.
    Moustaqim-Barrette A; Papamihali K; Mamdani Z; Williams S; Buxton JA
    PLoS One; 2020; 15(9):e0238618. PubMed ID: 32915834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do electronic health record prompts increase take-home naloxone administration for emergency department patients after an opioid overdose?
    Marino R; Landau A; Lynch M; Callaway C; Suffoletto B
    Addiction; 2019 Sep; 114(9):1575-1581. PubMed ID: 31013394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Take-Home Naloxone and risk management from the perspective of people who survived an opioid overdose in Stockholm - An analysis informed by drug, set and setting.
    Holmén E; Hammarberg A; Kåberg M; Storbjörk J
    Int J Drug Policy; 2023 May; 115():104021. PubMed ID: 37011507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation.
    McDonald R; Campbell ND; Strang J
    Drug Alcohol Depend; 2017 Sep; 178():176-187. PubMed ID: 28654870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Who is using take-home naloxone? An examination of supersavers.
    Eide D; Lobmaier P; Clausen T
    Harm Reduct J; 2022 Jun; 19(1):65. PubMed ID: 35717240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the life-saving potential of naloxone: A systematic review and descriptive meta-analysis of take home naloxone (THN) programmes for opioid users.
    McAuley A; Aucott L; Matheson C
    Int J Drug Policy; 2015 Dec; 26(12):1183-8. PubMed ID: 26508033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Overdose Response with Take Home Naloxone (ORTHN) project: Evaluation of health worker training, attitudes and perceptions.
    Monds LA; Bravo M; Mills L; Malcolm A; Gilliver R; Wood W; Harrod ME; Read P; Nielsen S; Dietze PM; Lenton S; Bleeker AM; Lintzeris N
    Drug Alcohol Rev; 2022 Jul; 41(5):1085-1094. PubMed ID: 35442514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.